Showing results (11-20 of 237) with videos related to
Sort By:
Pageof 24
Current Pharmaceutical Design|September 8, 2010
Vitamin D and metabolic syndrome: is there a link?Matilda Florentin, Moses S Elisaf, Dimitri P Mikhailidis, et al.Current Pharmaceutical Design|October 12, 2018
Prevalence, Identification, and Scouting for Familial Hypercholesterolaemia Including RegistriesMatilda Florentin, Michael S Kostapanos, Moses S Elisaf, et al.Current Vascular Pharmacology|October 31, 2013
Hemostatic factors and the metabolic syndromeMichael S Kostapanos, Matilda Florentin, Moses S Elisaf, et al.Journal of Cardiovascular Pharmacology and Therapeutics|April 28, 2012
Effects of statin monotherapy versus statin plus ezetimibe combination on serum uric acid levelsElisavet Moutzouri, Evangelos N Liberopoulos, Matilda Florentin, et al.Current Vascular Pharmacology|February 15, 2011
Pleiotropic effects of nicotinic acid: beyond high density lipoprotein cholesterol elevationMatilda Florentin, Evangelos N Liberopoulos, Anastazia Kei, et al.Journal of Clinical Hypertension (Greenwich, Conn.)|July 16, 2010
Comparison of hemoglobin A1c and fasting glucose criteria to diagnose diabetes among people with metabolic syndrome and fasting glucose above 100 mg/dL (5.5 mmol/L)Evangelos N Liberopoulos, Matilda Florentin, Anastazia Kei, et al.Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|November 17, 2010
Review: Antiplatelet drugs: what comes next?Anastazia A Kei, Matilda Florentin, Dimitri P Mikhailidis, et al.Current Medical Research and Opinion|January 29, 2011
The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemiaMatilda Florentin, Evangelos N Liberopoulos, Elisavet Moutzouri, et al.Current Vascular Pharmacology|February 26, 2010
Effect of non-statin lipid lowering and anti-obesity drugs on LDL subfractions in patients with mixed dyslipidaemiaMatilda Florentin, Alexadros D Tselepis, Moses S Elisaf, et al.Metabolic Syndrome and Related Disorders|March 1, 2011
Combining rosuvastatin with sartans of different peroxisome proliferator-activated receptor-γ activating capacity is not associated with different changes in low-density lipoprotein subfractions and plasma lipoprotein-associated phospholipase A₂Christos V Rizos, Evangelos N Liberopoulos, Constantinos C Tellis, et al.Pageof 24